The Application of Gonadotropin-Releasing Hormone Agonists in Non-Malignant Ovarian Tumor Patients

祝洪澜,李小平,王朝华,王悦,崔恒,王建六,魏丽惠
2014-01-01
Abstract:Objective: To observe the clinical effect of gonadotropin-releasing hormone agonists( GnRHa) cotreatment during chemotherapy in non-malignant ovarian tumor patients who had undergone the conservative surgery. Methods: The clinical data of 18 patients who were treated with fertility preservation surgery for non-malignant ovarian tumors and then administered GnRHa during chemotherapy( study group) in Peking University People's Hospital from January 2006 to December 2011 were retrospectively analyzed. This group was compared with a control group of 18 women who were treated concurrently with similar chemotherapy( n =6) without GnRHa or were historical controls( n = 12). The disease recurrence,the menstruation status and reproductive outcome were followed up and compared between the two groups. Results: One patient( 5. 6%) in the study group while 2 patients( 11. 1%) in the control group relapsed 2 years after conclusion of the primary treatment. All of the 18 women( 100. 0%) in the study group compared with 12 of the 18 patients in the control group( 66. 7%) resumed normal menses 6 months after the termination of the treatment( P0. 05). There were 5 spontaneous pregnancies in the study group( natural pregnancy rate: 83. 3%) while 2 in the control group( natural pregnancy rate: 33. 3%),all of the neonates were healthy. Conclusions: GnRHa administration before and during chemotherapy in non-malignant ovarian tumors patients who have undergone fertility preservation operation may bring up higher rates of spontaneous resumption of menses and a better pregnancy rate. Long-term follow up and large scale clinical studies are required to confirm the conclusion.
What problem does this paper attempt to address?